Telix Pharmaceuticals signs deal to acquire QSAM Biosciences for upto $123m
MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). The purchase price comprises US$33.1 million upfront, which is payable in the form of 4,369,914 Telix ordinary shares…